Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kevin Grogan
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
MabThera revenues sink 16% in Europe as the first biosimilars make in-roads into the market but the Swiss major is encouraged by another stellar performance from new MS drug Ocrevus.
The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.
The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.
The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'
No European approval recommendation for Roche multiple sclerosis drug Ocrevus but the Swiss major tells Scrip it is hopeful of getting approval within four months.